Article
OPTIMIZING ADJUNCTIVE IOP-LOWERING THERAPY: Rationale and Benefits for Prescribing Istalol®
Ideally, control of elevated IOP in patients with ocular hypertension or glaucoma might be achieved with monotherapy. However, published data indicate that treatment with a single modality is often not enough. In the Ocular Hypertension Treatment Study, which enrolled a generally healthy cohort and set a relatively modest therapeutic goal of a ?20% IOP reduction, 40% of patients needed 2 medications and 10% required 3 medications to reach this goal. These results are consistent with those in other publications and my clinical experience.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
